Funding round brings in $25 million for Versartis

01/16/2013 | American City Business Journals

Versartis secured $25 million from new and existing investors in a Series C financing round. Proceeds will support clinical trials of VRS-317, an investigational once-monthly form of recombinant human growth hormone designed for children with growth hormone deficiency. "With this substantial funding, we are able to continue our comprehensive development program for VRS-317, including obtaining proof-of-concept efficacy results and preparing for the launch of a Phase III trial in 2014," Versartis CEO Jeffrey Cleland said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC